Vor Biopharma

Vor Biopharma P/S

(Price-Sales Ratio) is an important metric for stock valuation. It is calculated by dividing the current share price by the revenue per share. The P/S indicates how many years a company needs to generate the revenue per share as profit. A low P/S suggests that a stock may be undervalued, while a high P/S could indicate overvaluation. However, it is important to always consider the P/S in the context of the industry and the company. of Vor Biopharma (VOR) as of Oct 26, 2026.

P/S

-

Last updated:

As of Oct 26, 2026, Vor Biopharma's P/S ratio stood at -, a % change from the - P/S ratio recorded in the previous year.

The Vor Biopharma P/S history

The Vor Biopharma P/S history
YEARP/SYoY
est43.17—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Vor Biopharma Valuation

Details

Historical Valuation Multiples

ⓘ

Price-to-Earnings Ratio (P/E)

The P/E ratio divides Vor Biopharma's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates Vor Biopharma's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots Vor Biopharma's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if Vor Biopharma grows earnings faster than its peers.

Vor Biopharma Stock analysis

What does Vor Biopharma do? Vor Biopharma develops cell therapies for cancer treatment, focusing on hematological malignancies. The company's proprietary platform combines patient engineering with targeted therapies, using expertise in hematopoietic stem cell biology and genome engineering. Its lead product candidate, tremtelectogene empogeditemcel (trem-cel), is designed to replace standard transplant care for acute myeloid leukemia (AML) and other blood cancers. The company conducts clinical trials such as VBP101, a Phase I/II study of VOR33 for AML patients. Vor Biopharma's revenue model relies on developing and advancing its cell therapy pipeline, with trem-cel as the primary focus. The company targets patients with AML and other blood cancers in transplant settings, aiming to replace current standard treatments. Clinical trials like VBP101 are critical for advancing its product candidates toward regulatory approval and commercialization. The firm's financial strategy centers on progressing its lead product through clinical trials to secure market approval. Trem-cel is positioned to address unmet needs in AML treatment, with VBP101 serving as a key study to demonstrate efficacy and safety. As a biopharmaceutical company, Vor Biopharma generates revenue through future product sales after regulatory approval, with no current commercial products. Vor Biopharma is one of the most popular companies on Eulerpool.

P/S Details

Decoding Vor Biopharma's P/S Ratio

Vor Biopharma's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.

Year-to-Year Comparison

Comparing Vor Biopharma's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.

Impact on Investments

The P/S ratio is instrumental for investors evaluating Vor Biopharma's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.

Interpreting P/S Ratio Fluctuations

Variations in Vor Biopharma’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.

Frequently Asked Questions about Vor Biopharma stock

On Eulerpool you can find the complete historical development of (Price-Sales Ratio) is an important metric for stock valuation. It is calculated by dividing the current share price by the revenue per share. The P/S indicates how many years a company needs to generate the revenue per share as profit. A low P/S suggests that a stock may be undervalued, while a high P/S could indicate overvaluation. However, it is important to always consider the P/S in the context of the industry and the company. Vor Biopharma since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Sales Ratio (P/S Ratio) is a financial metric that represents the ratio between the current price of a stock and the sales per share of the company. It is commonly used to assess the valuation of a stock compared to other stocks in the same industry or compared to the overall average of the stock market.

P/S Formula:
P/S = Price of a stock / Sales of a stock
If you can't find the Sales per Share (SPS) right away, which is the equivalent term for Revenue per Share in English, you can also calculate this value by dividing the company's total sales by the number of issued shares.

SPS Formula:
Total sales of the company / Number of issued shares
The Sales per Share or Revenue per Share can usually be easily found on most financial websites.

The P/S ratio is often used to assess the valuation of a stock compared to other stocks in the same industry or the overall stock market average. It can provide insights into how well the company is performing in terms of revenue per share compared to its competitors. A low P/S ratio may indicate that the company is generating relatively high revenue per share compared to other companies in the industry, which can be positive. On the other hand, a high P/S ratio may indicate that the company is generating relatively low revenue per share compared to its competitors, which can be negative.

To evaluate (Price-Sales Ratio) is an important metric for stock valuation. It is calculated by dividing the current share price by the revenue per share. The P/S indicates how many years a company needs to generate the revenue per share as profit. A low P/S suggests that a stock may be undervalued, while a high P/S could indicate overvaluation. However, it is important to always consider the P/S in the context of the industry and the company.'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for (Price-Sales Ratio) is an important metric for stock valuation. It is calculated by dividing the current share price by the revenue per share. The P/S indicates how many years a company needs to generate the revenue per share as profit. A low P/S suggests that a stock may be undervalued, while a high P/S could indicate overvaluation. However, it is important to always consider the P/S in the context of the industry and the company..

A 'good' varies by industry and company stage. On Eulerpool, you can compare (Price-Sales Ratio) is an important metric for stock valuation. It is calculated by dividing the current share price by the revenue per share. The P/S indicates how many years a company needs to generate the revenue per share as profit. A low P/S suggests that a stock may be undervalued, while a high P/S could indicate overvaluation. However, it is important to always consider the P/S in the context of the industry and the company.'s Vor Biopharma with sector peers and the industry average to assess whether it is attractive.

The P/S ratio when valuing a stock.

The price-to-sales ratio (P/S ratio) is an important tool of technical analysis that assists investors in evaluating stocks. It refers to the earnings per share of a company and its price movements. This indicator can be used to determine a stock's fair value, relative to the company's earnings.

History of the Price-to-Sales Ratio

The price-to-sales ratio is a relatively new indicator. It was first used in the 1980s by John Price when he developed the Price-to-Sales Index (PSI). Price wanted to find a way to value stocks taking into account their earnings. He noticed that many stock prices were not in line with their earnings situation. The PSI has since become an important analytical tool and is often referred to as the P/S ratio.

Calculation of the price-to-sales ratio

The price-to-sales ratio is easy to calculate. It is determined by dividing the current stock price by the company's earnings per share. P/S ratio = Stock price / Earnings per share. For example, if a company's stock price is $10 and the earnings per share is $2, then the P/S ratio is 5.

Application of the Price-to-Sales Ratio

The Price-to-Sales ratio is a useful tool for determining a fairly valued stock price. A low P/S ratio may indicate that a stock price is undervalued, which could be a good entry opportunity. However, a high Price-to-Sales ratio may indicate that a stock price is overvalued and investors should exercise caution.

An example: A company has a stock price of 20 USD and an earnings per share of 2 USD. The P/E ratio is 10. This could indicate that the stock price is overvalued and investors should be cautious before buying.

Investors and the price-to-sales ratio

Investors use the price-to-sales ratio to determine whether a company's stock price is fairly valued or not. They can compare the P/S ratio to see how the stock price relates to the company's earnings. Investors can also observe the P/S ratio over a longer period of time to see if the stock price changes in relation to the company's earnings.

Advantages and Disadvantages of the Price-to-Sales Ratio

The greatest advantage of the price-to-sales ratio is that it is a simple and understandable tool to determine the fair value of a stock price. It can also help investors identify stocks that are undervalued. One disadvantage is that the P/S ratio does not provide information about the company's profits. Therefore, investors should also consider other financial ratios before investing.

In today's time, the price-to-sales ratio is an important tool for investors to evaluate stocks and identify potential investment opportunities. It can help find a fairly valued stock price and identify stocks that are undervalued. However, investors should also consider other financial indicators before making an investment decision.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Valuation — Vor Biopharma

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — Vor Biopharma